Partnerships
Our Partners
Radius Health has established a global footprint through ex-U.S. partnerships to support the registration and commercialization of TYMLOS®. We work closely with partners who share our goal of improving the lives of patients with osteoporosis.
- Abaloparatide is marketed as TYMLOS® and ELADYNOS® outside the U.S., with the exception of Japan, where abaloparatide acetate is marketed as OSTABALO®. TYMLOS® and ELADYNOS® are registered trademarks of Radius Health, Inc, and OSTABALO® is a registered trademark of Teijin.
Partner With Us
In the U.S., Radius Health has a strong commercial infrastructure with a proven track record of success. We are seeking to expand our collaborative network to in-license and commercialize externally sourced therapeutics in our core areas of focus and expertise.
Do you have a partnership opportunity that addresses the following?
- Commercial or advanced clinical stage product(s)?
- Products in the Endocrinology, Rheumatology, Women’s Health or related specialty therapeutic areas?
- Products with growth potential that would benefit from the support of a highly experienced commercial team and sales force with a proven track record of success?
If so, and you are interested in pursuing a partnership opportunity with Radius Health and/or have a compelling product or technology you believe would benefit our pipeline, we welcome you to contact us by using the form below.